Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT24004
- Development stage
- Preclinical
- Lead developer
- BioNxt Solutions
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Sublingual
01
Overview
BNT24004 is an investigational drug developed by BioNxt Solutions for longevity and anti-aging therapies. It utilizes a sublingual thin-film delivery system designed to enhance the bioavailability of its active ingredient by bypassing the gastrointestinal tract and first-pass liver metabolism, resulting in faster absorption and more consistent pharmacokinetics. The product aims to address age-related decline, with early trials suggesting potential benefits such as slowing ovarian aging and possibly extending fertility. As of early 2025, BNT24004 is in preclinical development, with plans for further studies and regulatory advancement[1][2].
Beyond the preview
Go deeper on BNT24004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT24004.